GLP1R and type 2 diabetes mellitus: GLP‐1 RAs have been available as injectable formulations since exenatide received FDA approval in 2005 and as oral formulations since semaglutide was approved in 2019,8 trials have demonstrated significant weight and HbA1c reduction benefits of GLP‐1 RA compared with standard of care in patients with type 2 diabetes at high cardiovascular risk.9, 10